Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | GALR1 | P47211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966415 | 0.81 | KDM1A (0.48) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL17517026 | 0.73 | PDE2A (0.32) | PDE2A | |
| SCHEMBL15108851 | 0.72 | ACHE (0.44) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL4623454 | 0.71 | PDE2A (0.33) | PDE2A | |
| SCHEMBL170090 | 0.71 | — | — | |
| SCHEMBL25037230 | 0.70 | ALDH1A1 (0.42) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL17768674 | 0.70 | KDM1A (0.41) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL816860 | 0.70 | ACHE (0.52) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL1633970 | 0.70 | CYP3A4 (0.52) | KDM1AAKR1C3AKR1C2 | |
| SCHEMBL3962 | 0.70 | ALDH1A1 (0.42) | KDM1AAKR1C3AKR1C2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376384-B2 | Diaryliodonium salt | UBE INDUSTRIES, LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9376384-B2 | Diaryliodonium salt | UBE INDUSTRIES, LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20160046566-A1 | DIARYLIODONIUM SALT | UBE INDUSTRIES, LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046566-A1 | DIARYLIODONIUM SALT | UBE INDUSTRIES, LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-8404893-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-8008352-B2 | N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| CN-100579960-C | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA GMBH | 2010-01-13 | — | — | CN | disclosed |
| US-20090233943-A9 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | US | disclosed |
| WO-2008150217-A1 | 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONE ANALOGS FOR THE INHIBITION OF BETA-SECRETASE | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080287460-A1 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| CN-1878753-A | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA GMBH (DE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1653044-A | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GM (DE) | 2005-08-10 | — | — | CN | disclosed |
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046566-A1 | DIARYLIODONIUM SALT | AGTR2, KCNA5, AGTR1 | KDM1A 1441/4885AKR1C3 597/4885AKR1C2 421/4885 |
| US-20080287460-A1 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | KDM1A 2603/4885AKR1C3 2874/4885AKR1C2 2927/4885 |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | KDM1A 3739/4885AKR1C3 2729/4885AKR1C2 3013/4885 |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | KDM1A 3739/4885AKR1C3 2729/4885AKR1C2 3013/4885 |
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | KDM1A 2494/4885AKR1C3 589/4885AKR1C2 1040/4885 |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | TNNI3, TNNT2, SDHB | KDM1A 3563/4885AKR1C3 2694/4885AKR1C2 2927/4885 |
| US-20090233943-A9 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | KDM1A 2603/4885AKR1C3 2874/4885AKR1C2 2927/4885 |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | KDM1A 2494/4885AKR1C3 589/4885AKR1C2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.